Recently, our study revealed the activation and adaptive suppression of UPR to PI*Z AAT in human hepatocellular and murine models [22], suggesting that UPR may be serve as a therapeutic target for treatment of AATD-associated liver disease. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.